The increase in price target by Goldman Sachs from $47 to $56, while maintaining a Neutral rating, suggests a positive outlook on Ovintiv's stock value in the short term. This adjustment reflects an expectation of stronger performance or favorable market conditions for Ovintiv, likely leading to increased investor interest and potentially a rise in stock price.